Mental Wellness Portfolio
Invest in the future of mental healthcare. These carefully selected companies are leveraging technology to make mental health treatment more accessible, personalized, and effective, creating significant growth opportunities in an expanding market.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
Mental health is evolving from a niche concern to a mainstream priority. Companies using technology to break down barriers to care are positioned to capture significant value as digital solutions become the new standard for accessible, affordable mental healthcare.
What You Need to Know
This portfolio spans telehealth platforms, digital therapeutics, wearable technology, and next-generation treatments. These companies benefit from increased insurance coverage and growing employer adoption, creating multiple pathways to market expansion and revenue growth.
Why These Stocks
We've selected innovators at different stages of development—from established telehealth providers to cutting-edge biotechs exploring novel treatments. Each company offers unique exposure to the expanding mental wellness ecosystem through validated, scalable technology solutions.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+175.23%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 175.23% over the next year.
Stocks Rated Buy by Analysts
8 of 11 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 12% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
The $300B Opportunity
The global mental health market is projected to reach nearly $300 billion by 2027, with digital solutions capturing an increasingly large slice of this expanding pie.
Breakthrough Treatments Coming
Several companies in this portfolio are pioneering revolutionary treatments using psychedelics and digital therapeutics that could transform care for conditions resistant to traditional approaches.
From Stigma to Smartphone
As mental health becomes destigmatized, companies making care accessible through technology are seeing explosive user growth and increasing insurance coverage.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Nvidia's China Chip Pivot
Nvidia is developing a new, compliant AI chip for China, aiming to recapture market share lost to U.S. export controls. This strategic pivot creates a ripple effect, potentially benefiting the entire semiconductor supply chain that supports the production and deployment of this advanced hardware.
Navigating The Autonomous Driving Shakeout
A class-action lawsuit against Tesla regarding its Full Self-Driving claims puts the company's marketing and technology under intense scrutiny. This legal challenge could boost demand for competing autonomous driving technologies, creating opportunities for companies that supply advanced sensors and software.
Frequently Asked Questions
Everything you need to know about the product and billing.